SCHEMBL2930333

SCHEMBL2930333

NC(=O)[C@@H]1[C@@H]2C[C@@H]2CN1C(=O)c1ccccc1-c1csc(N)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.39
HSD17B10 Q99714 2/20 0.38
MPL P40238 1/20 0.38
PIK3CA P42336 1/20 0.37
RAB9A P51151 4/20 0.36
NPC1 O15118 2/20 0.36
SIRT1 Q96EB6 1/20 0.36
HCRTR2 O43614 5/20 0.35
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
KMT2A Q03164 2/20 0.34
TYR P14679 1/20 0.34
KDM4E B2RXH2 1/20 0.34
THRB P10828 1/20 0.34
ALOX15 P16050 1/20 0.34
PPARG P37231 1/20 0.34
NCOA2 Q15596 1/20 0.34
HCRTR1 O43613 4/20 0.34
ALOX5AP P20292 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3412070 1.00 SMN1; SMN2 (0.39) SMN1; SMN2HSD17B10MPLPIK3CARAB9A
SCHEMBL2930336 0.84 HCRTR1 (0.37) SMN1; SMN2HSD17B10MPLRAB9ANPC1
SCHEMBL3412075 0.84 HCRTR1 (0.37) SMN1; SMN2HSD17B10MPLRAB9ANPC1
SCHEMBL3415640 0.82 TSHR (0.46) HCRTR2HCRTR1
SCHEMBL2930537 0.82 TSHR (0.46) HCRTR2HCRTR1
SCHEMBL3409706 0.79 HCRTR1 (0.46) HCRTR2HCRTR1
SCHEMBL2923799 0.78 HCRTR1 (0.47) PIK3CAHCRTR2KMT2AHCRTR1
SCHEMBL2925286 0.78 HCRTR1 (0.44) HCRTR2MEN1ALDH1A1KMT2AHCRTR1
SCHEMBL2924530 0.78 SLC6A4 (0.41) HSD17B10RAB9ANPC1HCRTR2ALOX15
SCHEMBL2931896 0.78 HCRTR2 (0.44) HCRTR2HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079690-B1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-09-15 EP claimed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US claimed
EP-2079690-B1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-09-15 EP disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 SMN1; SMN2 3816/4885HSD17B10 1770/4885MPL 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.